The MICs and MBCs of ciprofloxacin were determined for clinical isolates of antibiotic-resistant aerobic bacteria. Decreased susceptibility to ciprofloxacin of cefotaxime-and amikacin-resistant Serratia marcescens and amikacin-resistant Pseudomonas aeruginosa strains were noted. The data suggest that ciprofloxacin susceptibility should be carefully monitored in treating patients with hospital-acquired bacterial infections.
Ciprofloxacin is highly active against most aerobic grampositive and -negative bacteria in vitro (1, 3, 5, 7, 21) . Primary resistance to ciprofloxacin among aerobic pathogens is rare (6, 12) . However, resistant strains may be isolated after treatment (4, 12, 14) , and mutants may be selected in the laboratory by exposure to this agent (16) . In this study, we report a significantly decreased susceptibility to ciprofloxacin among cefotaxime-and amikacin-resistant nosocomial pathogens not previously exposed to this class of antibiotic.
(Parts of this work were presented at the 14th International Congress of Chemotherapy, Kyoto, Japan, 23 to 28 June 1985.)
Organisms. The organisms used in this study were clinical isolates that were recovered and identified by standard techniques in the Clinical Microbiology Laboratory of the New York Veterans Administration Medical Center. The N.J., and amikacin was obtained from Bristol Laboratories, Syracuse, N.Y. The antibiotics were dissolved in sterile water and diluted in sterile medium for each experiment.
Susceptibility tests. Antibiotic susceptibilites were determined by macrotube dilution as described by the National Committee for Clinical Laboratory Standards (20) . Serial twofold dilutions of the antibiotics were prepared in MuellerHinton Broth (Difco Laboratories, Detroit, Mich.) supplemented with calcium and magnesium (50 and 25 mg/liter, respectively). Samples of 105 bacteria were added to a final volume of 1 ml to aliquots of the antibiotic broth solutions in glass tubes, and after gentle agitation, these were incubated at 35°C. The MIC of the antibiotic was defined as the lowest concentration which inhibited visible growth (turbidity) in the broth mixtures after overnight incubation. Clear tubes were subcultured onto antibiotic-free Mueller-Hinton agar (Difco) with a calibrated 0.01-ml sterile loop to determine the MBC of the antibiotic. This was defined as the lowest concentration of the antibiotic that killed 99.9% of the inoculum. Susceptibilities of gram-negative bacteria to ciprofloxacin, cefotaxime, and amikacin were tested simultaneously. Criteria for determining susceptibility and resistance to amikacin (MIC 2 64 ,ug/ml) and cefotaxime (MIC 2 64 ,ug/ml) were as previously described (20) . A referencc strain of Pseudomonas aeruginosa (ATCC 27853) or Escherichia coli (ATCC 25922) was included in each run with the In preliminary studies, we found that most of the clinical isolates of aerobic gram-negative bacteria tested were susceptible to amikacin and cefotaxime, and that these organisms were also exquisitely susceptible to ciprofloxacin (data not shown). However, a substantial number of the Klebsiella pneumoniae, Serratia marcescens, and P. aeruginosa isolates tested were resistant to amikacin. There was no difference in the ciprofloxacin susceptibilities of the amikacin-susceptible and -resistant K. pneumoniae strains (Table 1) . However, amikacin-resistant S. marcescens and P. aeruginosa isolates were significantly more resistant to ciprofloxacin than were the amikacin-susceptible organisms.
Of the P. aeruginosa strains, 70% were resistant to cefotaxime, and there was no difference in ciprofloxacin susceptibility among these organisms (Table 2) . However, S. marcescens strains that were resistant to cefotaxime were more resistant to ciprofloxacin than were the cefotaximesusceptible isolates. Of the 20 S. marcescens strains tested, 9 were susceptible to cefotaxime and amikacin, and 8 were resistant to both. The mean (+ standard deviation) MIC of ciprofloxacin for the susceptible organisms was 0.243 (±0.12) ,ug/ml (range, 0.06 to 0.5 ,ug/ml), and the mean (± standard deviation) MIC for resistant strains was 1.25 (±0.46) ,ug/ml (range 1 to 2 jig/ml) (P c 0.001).
The activity of ciprofloxacin against gram-positive bacteria was recorded (Table 3) . Ciprofloxacin was active against methicillin-susceptible and -resistant S. aureus and Staphylococcus epidermidis, penicillin-susceptible and -resistant Streptococcus pneumoniae strains, and enterococci.
Ciprofloxacin has remarkably broad-spectrum activity against aerobic bacteria in vitro (1, 3, 5, 7, 21) , and it is effective in treating experimental (9, 17, 19) and clinical infections (6, 12 (15) .
At the time that our study was performed, the newer quinolone antibiotics had not been used in this hospital. We have previously noted a high level of amikacin resistance among nosocomial pathogens studied, including K. pneumoniae, S. marcescens, and P. aeruginosa (11) . Our data suggest that some cross-resistance to ciprofloxacin occurred among these organisms, particularly P. aeruginosa strains. The cefotaxime-and amikacin-resistant S. marcescens strains were less susceptible to ciprofloxacin than the susceptible strains were, but most were inhibited by clinically achievable concentrations of the antibiotic (2, 6, 8, 12) .
The decreased susceptibility to ciprofloxacin among amikacin-resistant P. aeruginosa strains and cefotaxime-and amikacin-resistant S. marcescens strains suggests that this antibiotic should be used with caution in institutions where resistance to the newer cephalosporins and amikacin exists. b Penicillin susceptibility was determined by tube and agar dilution (18) . An MIC of <0.1 ,ug/ml indicated susceptibility; an MIC of -0.1 pLg/ml indicated resistance.
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